Plausible targets,
before consensus forms.
Eight autonomous agents monitor biomedical literature, clinical trials, and commercial signals — surfacing ADC drug targets ranked by therapeutic alpha.
Plausible ADC targets, ranked by signal.
Signal to decision,
at machine speed.
Eight autonomous agents continuously monitor biomedical literature, clinical trials, regulatory filings, and commercial data — surfacing ranked opportunities in real time.
Click View Details on any target below to open the full diligence suite — clinical simulations, regulatory pathway, market sizing, and BD analysis.
Tissue Factor ADC
New trial activity combined with high target expression data and significant commercial whitespace in the 2L+ setting.
CLDN18.2 ADC
Strong target rationale and validated clinical precedent, but increasingly crowded competitive landscape demands a differentiation thesis.
Nectin-4 ADC Expansion
Label expansion potential across multiple solid tumor types, backed by known ADC structural precedent from the approved urothelial program.
B7-H4 ADC
Emerging target interest with early-phase clinical signals, but failure-risk flags from hematologic toxicity precedents require de-risking before advancement.
- Trial Agent found 2 new ADC studies in cervical cancer4m ago
- Literature Agent extracted 14 target-expression signals across 3 candidates12m ago
- Failure Agent flagged hematologic toxicity precedent in B7-H4 program28m ago
- Commercial Agent identified 2L+ cervical whitespace in competitive landscape41m ago
- Structure Agent found predicted AlphaFold structure candidate for VTCN11h ago